RAC 5.59% $1.70 race oncology ltd

RAC - Charts & Price Action, page-296

  1. 11,249 Posts.
    lightbulb Created with Sketch. 29637
    Yes. Next year. A few factors.
    • Success in trials (previous results suggest success)
    • Keeping dilution in check (management have been doing a good job to date)
    • Increased awareness (I think an overseas listing should occur before new trials readout)
    • Parallel catalysts for both AML and Breast Cancer (breast cancer will help to increase interest in what RACE are doing as it is a higher-profile cancer)
    Look at PAR. $700M market cap. Still a long way for them to achieve approval.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.